Odds of prescription rise with increasing age, increasing BMI, abnormal lab testing, non-Hispanic White or Hispanic race, ethnicity ...

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...

Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.

Meta-analysis of 64 clinical trials 'should give clinicians and their patients more confidence,' say Hopkins researchers ...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, ...

GLP-1 RAs appear to be helping people reduce medication use and limit trips to the emergency department for chronic migraine treatment.

A novel GLP-1 receptor agonist (RA) pill called orforglipron leads to a larger reduction in blood sugar levels after a year ...

HealthDay News — Adults with overweight or obesity regain much of their lost weight after cessation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a review published online ...

A meta-analysis shows GLP-1 RA therapy does not significantly lower vascular dementia events compared with placebo in high-risk patient groups.

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy ...

GLP-1 RA use was associated with significant weight loss in patients with IBD and obesity and/or T2D, with mean differences of -9.1 kg in semaglutide users, -9 kg in liraglutide users, and -11.6 kg in ...

GLP-1 RAs are prescribed to about 20% of potentially eligible adolescents, with increasing odds based on several individual factors.